Skip to main content

Research Repository

Advanced Search

Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33

Tarr, Alexander W.; Owsianka, Ania M.; Timms, Judith M.; McClure, C. Patrick; Brown, Richard J.P.; Hickling, Timothy P.; Pietschmann, Thomas; Bartenschlager, Ralf; Patel, Arvind H.; Ball, Jonathan K.

Authors

Ania M. Owsianka

Judith M. Timms

C. Patrick McClure

Richard J.P. Brown

Timothy P. Hickling

Thomas Pietschmann

Ralf Bartenschlager

Arvind H. Patel

Jonathan K. Ball



Abstract

The mouse monoclonal antibody (MAb) AP33, recognizing a 12 amino acid linear epitope in the hepatitis C virus (HCV) E2 glycoprotein, potently neutralizes retroviral pseudoparticles (HCVpp) carrying genetically diverse HCV envelope glycoproteins. Consequently, this antibody and its epitope are highly relevant to vaccine design and immunotherapeutic development. The rational design of immunogens capable of inducing antibodies that target the AP33 epitope will benefit from a better understanding of this region. We have used complementary approaches, which include random peptide phage display mapping and alanine scanning mutagenesis, to identify residues in the HCV E2 protein critical for MAb AP33 binding. Four residues crucial for MAb binding were identified, which are highly conserved in HCV E2 sequences. Three residues within E2 were shown to be critical for binding to the rat MAb 3/11, which previously was shown to recognize the same 12 amino acid E2 epitope as MAb AP33 antibody, although only two of these were shared with MAb AP33. MAb AP33 bound to a panel of functional E2 proteins representative of genotypes 1-6 with higher affinity than MAb 3/11. Similarly, MAb AP33 was consistently more efficient at neutralizing infectivity by diverse HCVpp than MAb 3/11. Importantly, MAb AP33 was also able to neutralize the cell culture infectious HCV clone JFH-1. In conclusion, these data identify important protective determinants and will greatly assist the development of vaccine candidates based on the AP33 epitope. Copyright © 2006 by the American Association for the Study of Liver Diseases.

Citation

Tarr, A. W., Owsianka, A. M., Timms, J. M., McClure, C. P., Brown, R. J., Hickling, T. P., Pietschmann, T., Bartenschlager, R., Patel, A. H., & Ball, J. K. (2006). Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology, 43(3), 592-601. https://doi.org/10.1002/hep.21088

Journal Article Type Article
Online Publication Date Feb 22, 2006
Publication Date 2006-03
Deposit Date Nov 9, 2022
Journal Hepatology
Print ISSN 0270-9139
Electronic ISSN 1527-3350
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 43
Issue 3
Pages 592-601
DOI https://doi.org/10.1002/hep.21088
Public URL https://nottingham-repository.worktribe.com/output/3129644
Publisher URL https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.21088